Brinton Pharmaceuticals has appointed Sathya Narayanan as Chief Executive Officer – India Cluster & JPAC (Japan Asia Pacific Cluster), marking a significant step in the company’s ongoing global expansion strategy. The appointment reflects Brinton’s commitment to strengthening its leadership presence across India, South Asia, Southeast Asia, and other high-growth healthcare markets.

A seasoned pharmaceutical industry leader, Sathya Narayanan brings over 20 years of experience in pharmaceuticals and dermatology, with a proven track record of driving business growth, building high-performing teams, and enhancing market leadership. Prior to joining Brinton, he served as Managing Director of Galderma South Asia/Emcutix.

Welcoming the appointment, Rahulkumar Darda, Chairman & Managing Director of Brinton Pharmaceuticals, highlighted the strategic importance of India and neighbouring markets in the company’s growth plans. He noted that Sathya’s industry expertise and leadership capabilities position him well to lead Brinton’s next phase of expansion.

Expressing his enthusiasm, Sathya Narayanan said Brinton’s strong foundation in innovation and scientific excellence creates significant opportunities to expand healthcare access and deliver differentiated therapies across the region.